US Markets for Interventional Cardiology Exceed $4 billion
Rising procedure volumes in the US have made interventional cardiology (IC), the minimally invasive medical specialty concerned with the treatment of CAD, a burgeoning and lucrative market. According to a new report published by Millennium Research Group (MRG), over 1 million Americans underwent a percutaneous coronary intervention (PCI) procedure in 2004, contributing partly to IC market revenue in excess of $4 billion.
(PRWEB) July 29, 2005 -— An aging baby boomer population at increased risk
for coronary artery disease (CAD) is driving US demand for less invasive
techniques to treat adverse cardiovascular conditions. Rising procedure volumes
in the US have made interventional cardiology (IC), the minimally invasive
medical specialty concerned with the treatment of CAD, a burgeoning and
lucrative market. According to a new report published by Millennium Research
Group (MRG), over 1 million Americans underwent a percutaneous coronary
intervention (PCI) procedure in 2004, contributing partly to IC market revenue
in excess of $4 billion.
The US IC market, comprising coronary stents,
percutaneous transluminal coronary angioplasty (PTCA) balloons, accessory
devices (PTCA guidewires, diagnostic catheters, PTCA guiding catheters,
intravascular ultrasound (IVUS) catheters, and introducer sheaths), and plaque
modification devices (coronary atherectomy, thrombectomy, embolic protection,
and chronic total occlusion devices), currently derives the majority of its
revenue from drug-eluting stents (DES). Because drug-eluting devices are
significantly more expensive than their bare-metal predecessors, conversion to
DES has contributed to the substantial growth of the US IC market over the last
2 years. As a result of continued adoption, over 99% of all stent procedures
will employ a DES by 2009.
While high market saturation will prompt DES
market growth to gradually subside over the next five years, the plaque
modification segment is set to flourish. Growth will be driven by the adoption
of embolic protection devices, which physicians are increasingly employing to
protect against stroke during interventional procedures. The use of atherectomy
devices will also increase over the next 5 years as more physicians elect to
perform atherectomies prior to implanting a DES.
US Markets for
Interventional Cardiology 2005 is part of MRG’s Global Interventional Cardiology
series, which offers in-depth analysis of IC-related markets in the US, Europe,
Japan, Latin America, and Asia Pacific. Global competitive coverage includes
Abbott Vascular (ABT), Boston Scientific (BSX), Cordis (JNJ), Guidant (GDT), and
Medtronic (MDT), among others. MRG has also launched the 2005 Marketfocus
series, offering brand- and quarter-level coverage of the US and European
markets for coronary stents, PTCA balloons, and accessory devices, as well as
the US market for plaque modification.
A leading source of competitive
intelligence, MRG is now the largest provider of medical device market research
in the world. Located in Toronto, Canada, MRG covers global markets and has
pioneered reporting of numerous emerging products.
Contact
Information:
Derrick Navarro
Millennium Research Group Inc
+1 (416)
364-7776 ext. 133
e-mail protected from spam bots
www.mrg.net ;
Canossa
Chan
Millennium Research Group Inc.
+1 (416) 364-7776 ext. 129
e-mail
protected from spam bots
www.mrg.net
# # #
Source : http://www.prweb.com/releases/2005/7/prweb266341.htm